142 related articles for article (PubMed ID: 8844481)
1. Effect of a cholecystokinin receptor antagonist (loxiglumide) on gallbladder contractile function in guinea pigs.
Tsubo K; Arai M; Omachi H; Mitamura K
J Gastroenterol; 1996 Aug; 31(4):578-81. PubMed ID: 8844481
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin antagonistic activities of loxiglumide.
Wakatsuki K; Saito T; Saeki M; Ninomiya K; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1997 Oct; 47(10):1130-3. PubMed ID: 9368707
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin receptor antagonist loxiglumide: influence on bilio-pancreatic secretion and gastrointestinal hormones in man.
Schmidt WE; Creutzfeldt W; Höcker M; Choudhury AR; Nustede R; Schleser A; Nitsche R; Rovati LC; Schafmayer A; Fölsch UR
Digestion; 1990; 46 Suppl 2():232-9. PubMed ID: 2262057
[TBL] [Abstract][Full Text] [Related]
5. Effect of loxiglumide on gallbladder contractile response to cerulein and food in humans.
Malesci A; De Fazio C; Festorazzi S; Bonato C; Valentini A; Tacconi M; Rovati L; Setnikar I
Gastroenterology; 1990 May; 98(5 Pt 1):1307-10. PubMed ID: 2323521
[TBL] [Abstract][Full Text] [Related]
6. Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.
Schmidt WE; Creutzfeldt W; Schleser A; Choudhury AR; Nustede R; Höcker M; Nitsche R; Sostmann H; Rovati LC; Fölsch UR
Am J Physiol; 1991 Feb; 260(2 Pt 1):G197-206. PubMed ID: 1996640
[TBL] [Abstract][Full Text] [Related]
7. The role of cholecystokinin and the cholinergic system in intravenous amino acid-induced gallbladder emptying.
Gielkens HA; de Boer SY; Lam WF; Rovati LC; Lamers CB; Masclee AA
Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1227-31. PubMed ID: 9471030
[TBL] [Abstract][Full Text] [Related]
8. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
Nakano S; Kihara Y; Otsuki M
Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
Taniguchi H; Yazaki N; Endo T; Nagasaki M
Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
[TBL] [Abstract][Full Text] [Related]
10. Effects of somatostatin and loxiglumide on gallbladder motility.
Lieverse RJ; Jansen JB; Jebbink MC; Masclee AA; Rovati LC; Lamers CB
Eur J Clin Pharmacol; 1995; 47(6):489-92. PubMed ID: 7768249
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of loxiglumide (CCK antagonist) inhibits postprandial gallbladder contraction without affecting gastric emptying.
Corazziari E; Ricci R; Biliotti D; Bontempo I; De Medici A; Pallotta N; Torsoli A
Dig Dis Sci; 1990 Jan; 35(1):50-4. PubMed ID: 2295294
[TBL] [Abstract][Full Text] [Related]
12. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
[TBL] [Abstract][Full Text] [Related]
13. Effects of loxiglumide on gallbladder emptying in healthy volunteers.
Niederau C; Heintges T; Rovati L; Strohmeyer G
Gastroenterology; 1989 Nov; 97(5):1331-6. PubMed ID: 2792664
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
[TBL] [Abstract][Full Text] [Related]
15. Elevation of feed intake in parasite-infected lambs by central administration of a cholecystokinin receptor antagonist.
Dynes RA; Poppi DP; Barrell GK; Sykes AR
Br J Nutr; 1998 Jan; 79(1):47-54. PubMed ID: 9505802
[TBL] [Abstract][Full Text] [Related]
16. Dose-response effects of oral loxiglumide on postprandial gall-bladder emptying in man.
Malesci A; De Fazio C; Festorazzi S; Bonato C; Valentini A; Tacconi M; Bekkering M; Giacovelli G; D'Amato M; Rovati LC
Arzneimittelforschung; 1992 Nov; 42(11):1359-62. PubMed ID: 1492852
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR
Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290
[TBL] [Abstract][Full Text] [Related]
18. Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers.
Schwarzendrube J; Niederau M; Lüthen R; Niederau C
Gastroenterology; 1991 Jun; 100(6):1683-90. PubMed ID: 2019374
[TBL] [Abstract][Full Text] [Related]
19. Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.
Lieverse RJ; Jansen JB; Masclee AA; Rovati LC; Lamers CB
Gut; 1994 Apr; 35(4):501-5. PubMed ID: 8174988
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
